共 167 条
[1]
Asa SL(2017)From pituitary adenoma to pituitary neuroendocrine tumor (PitNET): an International Pituitary Pathology Club proposal Endocr. Relat. Cancer 24 C5-C8
[2]
Casar-Borota O(2007)A prospective, multicentre study to investigate the efficacy, safety and tolerability of octreotide LAR (long-acting repeatable octreotide) in the primary therapy of patients with acromegaly Clin. Endocrinol. 66 859-868
[3]
Chanson P(2015)Octreotide LAR treatment of acromegaly in “real life”: long-term outcome at a tertiary care center Pituitary 18 290-296
[4]
Mercado M(2016)Historical response rates of somatostatin analogues in the treatment of acromegaly: a systematic review Endocr. Pr. 22 350-356
[5]
Borges F(2008)Prognostic significance of the Ki-67 labeling index in growth hormone-secreting pituitary adenomas J. Clin. Endocrinol. Metab. 93 2746-2750
[6]
Bouterfa H(2013)Ki-67 is a predictor of acromegaly control with octreotide LAR independent of SSTR2 status and relates to cytokeratin pattern Eur. J. Endocrinol. 169 217-223
[7]
Espinosa-de-los-Monteros AL(2013)Novel pathway for somatostatin analogs in patients with acromegaly Trends Endocrinol. Metab. 24 238-246
[8]
Gonzalez B(2016)Factors predicting pasireotide responsiveness in somatotroph pituitary adenomas resistant to first-generation somatostatin analogues: an immunohistochemical study Eur. J. Endocrinol. 174 241-250
[9]
Vargas G(2012)Endothelial expression of endocan is strongly associated with tumor progression in pituitary adenoma Brain Pathol. 22 757-764
[10]
Sosa E(2013)Over-expression of vascular endothelial growth factor in pituitary adenomas is associated with extrasellar growth and recurrence Pituitary 16 370-377